CoChat

Hybrid mass spectrometry approaches in glycoprotein analysis and their usage in scoring biosimilarity

Open access
Yang, Yang, Liu, Fan, Franc, Vojtech, Halim, Liem Andhyk, Schellekens, Huub, Heck, Albert J. R. · 2016 · Nature Communications

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Many biopharmaceutical products exhibit extensive structural micro-heterogeneity due to an array of co-occurring post-translational modifications. These modifications often effect the functionality of the product and therefore need to be characterized in detail. Here, we present an integrative approach, combining two advanced mass spectrometry-based methods, high-resolution native mass spectrometry and middle-down proteomics, to analyse this micro-heterogeneity. Taking human erythropoietin and the human plasma properdin as model systems, we demonstrate that this strategy bridges the gap between peptide- and protein-based mass spectrometry platforms, providing the most complete profiling of glycoproteins. Integration of the two methods enabled the discovery of three undescribed C-glycosylation sites on properdin, and revealed in addition unexpected heterogeneity in occupancies of C-mannosylation. Furthermore, using various sources of erythropoietin we define and demonstrate the usage of a biosimilarity score to quantitatively assess structural similarity, which would also be beneficial for profiling other therapeutic proteins and even plasma protein biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms13397

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic workflow of the hybrid MS approaches for the structural analysis of protein heterogeneity. High-resolution native MS is used to qualitatively and quantitatively profile all co-appearing proteoforms and middle-down proteomic experiments are performed to characterize each modification site. The data from the site-specific PTM characterization obtained by middle-down proteomics is used to construct a native MS spectrum. A standard Pearson correlation test is conducted between the constructed and experimental native MS spectra, or between different native MS spectra to quantitatively assess the structural similarities.
Figure 1 Schematic workflow of the hybrid MS approaches for the structural analysis of protein heterogeneity. High-resolution native MS is used to qualitatively and quantitatively profile all co-appearing proteoforms and middle-down proteomic experiments are performed to characterize each modification site. The data from the site-specific PTM characterization obtained by middle-down proteomics is used to construct a native MS spectrum. A standard Pearson correlation test is conducted between the constructed and experimental native MS spectra, or between different native MS spectra to quantitatively assess the structural similarities.CC BY · PubMed Central
Figure 2 Native MS analysis of rhEPO. (a) Schematic of the rhEPO backbone sequence and its reported PTM sites (Uniprot code: P01588). (b) The zero-charge deconvoluted native MS spectrum of rhEPO. The overall PTM compositions are assigned based on the accurate mass measurements of the intact protein. Each colour represents a glycan composition without sialic acids; the number of sialic acids attached are marked on top of each peak with the same colour. For example, the most abundant peak are marked in green and number 13, it corresponded to the glycan composition Hex22HexNAc19Fuc3Sia13. The additional +42 Da modifications represent the further O-acetylation of sialic acids (shown in filled circles), whereas the +16 Da modification indicates the replacement of NeuAc for NeuGc (shown in empty circles). (c) The zero-charge deconvoluted native MS spectrum and the overall PTM composition assignments rhEPO subjected to treatment by sialidase, which cleaves off all sialic acids present on rhEPO.
Figure 2 Native MS analysis of rhEPO. (a) Schematic of the rhEPO backbone sequence and its reported PTM sites (Uniprot code: P01588). (b) The zero-charge deconvoluted native MS spectrum of rhEPO. The overall PTM compositions are assigned based on the accurate mass measurements of the intact protein. Each colour represents a glycan composition without sialic acids; the number of sialic acids attached are marked on top of each peak with the same colour. For example, the most abundant peak are marked in green and number 13, it corresponded to the glycan composition Hex22HexNAc19Fuc3Sia13. The additional +42 Da modifications represent the further O-acetylation of sialic acids (shown in filled circles), whereas the +16 Da modification indicates the replacement of NeuAc for NeuGc (shown in empty circles). (c) The zero-charge deconvoluted native MS spectrum and the overall PTM composition assignments rhEPO subjected to treatment by sialidase, which cleaves off all sialic acids present on rhEPO.CC BY · PubMed Central
Figure 3 Middle-down proteomic analysis of rhEPO. PTM profiling of site-specific glycoforms of rhEPO, covering the three N-glycosylation sites N24 (a), N38 (c), N83 (d) and the O-glycosylation site S126 (b). Of note, all the presented triantennary N-glycans may contain two types of structural isomers: α1–3 triantennary (shown in the figure), and α1–6 triantennary structures. * indicates the possibilities of a second co-existing glycan structure in addition to the one shown in the figure. For example, a triantennary structure with two sialic acids can also be a diantennary structure with an extra Galβ-1,4GlcNAc unit; a tetra-antennary structure with three sialic acids can also be a triantennary structure with an extra Galβ-1,4GlcNAc unit. The triangles indicate additional modification of sialic acids by either O-acetylation (in orange) or the replacement of −CH3 by −CH2OH (in blue).
Figure 3 Middle-down proteomic analysis of rhEPO. PTM profiling of site-specific glycoforms of rhEPO, covering the three N-glycosylation sites N24 (a), N38 (c), N83 (d) and the O-glycosylation site S126 (b). Of note, all the presented triantennary N-glycans may contain two types of structural isomers: α1–3 triantennary (shown in the figure), and α1–6 triantennary structures. * indicates the possibilities of a second co-existing glycan structure in addition to the one shown in the figure. For example, a triantennary structure with two sialic acids can also be a diantennary structure with an extra Galβ-1,4GlcNAc unit; a tetra-antennary structure with three sialic acids can also be a triantennary structure with an extra Galβ-1,4GlcNAc unit. The triangles indicate additional modification of sialic acids by either O-acetylation (in orange) or the replacement of −CH3 by −CH2OH (in blue).CC BY · PubMed Central
Figure 4 Integrative analysis of rhEPO using both high-resolution native MS and middle-down proteomics data. (a,b) Comparison of the in silico constructed spectrum based on middle-down proteomic data (shown in blue) with the experimental native MS spectrum (shown in brown) before (a) or after (b) sialidase treatment. The Pearson correlation coefficient between the displayed spectra is shown at the top right.
Figure 4 Integrative analysis of rhEPO using both high-resolution native MS and middle-down proteomics data. (a,b) Comparison of the in silico constructed spectrum based on middle-down proteomic data (shown in blue) with the experimental native MS spectrum (shown in brown) before (a) or after (b) sialidase treatment. The Pearson correlation coefficient between the displayed spectra is shown at the top right.CC BY · PubMed Central
Figure 5 Comprehensive PTM characterization of properdin. (a) The properdin sequence and its known and novel PTM sites, wherein the three newly discovered mannosylation sites at W80, W202 and W318 are annotated in red. (b) The native MS spectrum of properdin, zoomed in at charge state [M+14H]14+. The overall PTM composition is annotated. (c) Relative abundances of peptide proteoforms were estimated from their XICs. Each PTM-modified peptide was normalized individually so that the sum of all its proteoform areas was set at 100%. For clarity, only parts of the peptide sequence with PTMs are shown below the graph. A more detailed look at the graph in b shows a certain variability of C-mannosylation occupancy in different TSRs; details on this heterogeneity are described in Supplementary Note 1. (d,e) The comparison of the constructed spectra without (d) or with (e) the three newly discovered C-mannosylation sites with the experimental native MS spectrum of properdin. The Pearson correlation coefficient between the displayed spectra is shown at the top left.
Figure 5 Comprehensive PTM characterization of properdin. (a) The properdin sequence and its known and novel PTM sites, wherein the three newly discovered mannosylation sites at W80, W202 and W318 are annotated in red. (b) The native MS spectrum of properdin, zoomed in at charge state [M+14H]14+. The overall PTM composition is annotated. (c) Relative abundances of peptide proteoforms were estimated from their XICs. Each PTM-modified peptide was normalized individually so that the sum of all its proteoform areas was set at 100%. For clarity, only parts of the peptide sequence with PTMs are shown below the graph. A more detailed look at the graph in b shows a certain variability of C-mannosylation occupancy in different TSRs; details on this heterogeneity are described in Supplementary Note 1. (d,e) The comparison of the constructed spectra without (d) or with (e) the three newly discovered C-mannosylation sites with the experimental native MS spectrum of properdin. The Pearson correlation coefficient between the displayed spectra is shown at the top left.CC BY · PubMed Central
Figure 6 Quantitatively assessing the similarity of different rhEPO therapeutics using high-resolution native MS. (a,b) Native MS spectra of three rhEPO products (rhEPO BRP, epoetin beta and epotein zeta) without (a) or with (b) sialidase treatment. (c) A heat map displaying spectra similarity between the three different rhEPO products. The numbers displayed in the heat map represent the Pearson correlation coefficients. Experimental duplicates are marked as beta and beta′, BRP and BRP′, zeta and zeta′. After removing sialic acids contents by sialidase, the Pearson correlation coefficients between EPO products increased, as shown in the heat map of desialylated EPO samples (d).
Figure 6 Quantitatively assessing the similarity of different rhEPO therapeutics using high-resolution native MS. (a,b) Native MS spectra of three rhEPO products (rhEPO BRP, epoetin beta and epotein zeta) without (a) or with (b) sialidase treatment. (c) A heat map displaying spectra similarity between the three different rhEPO products. The numbers displayed in the heat map represent the Pearson correlation coefficients. Experimental duplicates are marked as beta and beta′, BRP and BRP′, zeta and zeta′. After removing sialic acids contents by sialidase, the Pearson correlation coefficients between EPO products increased, as shown in the heat map of desialylated EPO samples (d).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

Metadata

Authors
Yang, Y., Liu, F., Franc, V., Halim, L. A., Schellekens, H., & Heck, A. J. R.
Affiliations
Utrecht University (NL)
Corresponding author
Heck, Albert J. R.
Venue
Nature Communications
Published
2016-11-08
Volume
7
Issue
1
Pages
13397-13397
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2551001349
Cited by
152
References
56
Citations by year
2026: 4 · 2025: 7 · 2024: 10 · 2023: 17 · 2022: 10 · 2021: 23 · 2020: 19 · 2019: 19 · 2018: 22 · 2017: 19 · 2016: 1
FWCI
10.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
  • European Commission (686547, HORIZON2020, 317371)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184.032.201, 686547, 718.015.003)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Physical Sciences › Chemistry › Spectroscopy › Mass Spectrometry Techniques and Applications
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
glycoprotein analysis, post-translational modification, C-glycosylation, C-mannosylation, erythropoietin, properdin, middle-down proteomics, plasma proteins, therapeutic proteins
MeSH terms
Amino Acid Sequence, Erythropoietin, Glycoproteins, Humans, Properdin, Protein Processing, Post-Translational, Recombinant Proteins, Mass Spectrometry, Proteomics, Biosimilar Pharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.